Published in BMC Cancer on June 15, 2011
Relevance of health economics in breast cancer treatment: integration of economics in the management of breast cancer at the clinic level. Breast Care (Basel) (2013) 1.08
Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer. Support Care Cancer (2013) 0.88
Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. Springerplus (2014) 0.85
Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. Breast Cancer (Dove Med Press) (2016) 0.84
Sequential Metastatic Breast Cancer Chemotherapy: Should the Median be the Message? Front Public Health (2013) 0.82
Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis. Springerplus (2014) 0.81
'Suspect molecular signature' in blood as the indicator of undiagnosed breast cancer, cancer risk and targeted prevention. EPMA J (2013) 0.78
Effect of a Nurse-Led Psychoeducational Intervention on Healthcare Service Utilization Among Adults With Advanced Cancer. Oncol Nurs Forum (2015) 0.78
Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study. BMC Health Serv Res (2015) 0.75
Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents. Int J Breast Cancer (2014) 0.75
Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe. BMC Cancer (2015) 0.75
Healthcare costs attributable to the treatment of patients with spinal metastases: a cohort study with up to 8 years follow-up. BMC Cancer (2015) 0.75
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst (2007) 6.08
Treatment of breast cancer. N Engl J Med (1998) 4.32
Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst (1995) 3.81
Estimating medical costs from incomplete follow-up data. Biometrics (1997) 3.25
The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics (2009) 1.56
The utility of Medicare claims data for measuring cancer stage. Med Care (1999) 1.54
Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J (2010) 1.51
Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat (2007) 1.30
Factors predictive of response to hormone therapy in breast cancer. Tumori (2008) 1.25
Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat (2004) 1.17
Cost of breast cancer treatment. A 4-year longitudinal study. Arch Intern Med (1996) 1.12
Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev (2003) 1.05
The economic burden of breast cancer in California. Breast Cancer Res Treat (2008) 0.96
Therapeutic options in the management of metastatic breast cancer. Oncology (Williston Park) (2008) 0.95
Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities. Clin Breast Cancer (2008) 0.90
Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest (2002) 6.13
Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2006) 5.86
The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med (2005) 4.25
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J (2013) 2.92
Population-wide benefits of routine vaccination of children against influenza. Vaccine (2005) 2.68
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med (2011) 2.62
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.54
Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis (2009) 2.41
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med (2010) 2.40
Long-term mortality and medical care charges in patients with severe sepsis. Crit Care Med (2003) 2.39
Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care (2003) 2.29
Therapy switching in patients receiving long-acting opioids. Ann Pharmacother (2004) 2.14
Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med (2005) 2.06
Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health (2004) 2.05
Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol (2005) 1.94
Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain (2004) 1.92
Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer (2006) 1.61
Is sepsis accurately coded on hospital bills? Value Health (2002) 1.60
Systematic review and meta-analysis of efficacy, safety, and tolerability data from randomized controlled trials of drugs used to treat postherpetic neuralgia. Ann Pharmacother (2011) 1.58
Organizational barriers to physician participation in cancer clinical trials. Am J Manag Care (2005) 1.56
Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease. Am J Manag Care (2009) 1.52
Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board. Cancer Invest (2002) 1.49
The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology (2004) 1.47
Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol (2008) 1.41
Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq. Vaccine (2009) 1.40
Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organization. Cancer (2004) 1.39
Opioid use and health care charges at the end of life in patients with metastatic cancer. Manag Care Interface (2004) 1.38
Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol (2006) 1.28
Health care use and costs associated with use of a health club membership benefit in older adults with diabetes. Diabetes Care (2008) 1.28
Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women. Int J Cancer (2002) 1.27
Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res (2005) 1.26
Economic costs of nonmedical use of prescription opioids. Clin J Pain (2011) 1.22
Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother (2006) 1.15
The safety net: a cost-effective approach to improving breast and cervical cancer screening. J Womens Health (Larchmt) (2003) 1.13
Risk of venous thromboembolism among hospitalized medically ill patients. Am J Health Syst Pharm (2006) 1.12
Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther (2009) 1.10
Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens (2007) 1.10
Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect (Larchmt) (2008) 1.09
Resource utilization and costs before and after total joint arthroplasty. BMC Health Serv Res (2012) 1.06
Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. Biol Psychiatry (2012) 1.05
The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer. Value Health (2002) 1.04
Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer (2006) 1.02
Clinical and economic outcomes for patients with health care-associated Staphylococcus aureus pneumonia. J Clin Microbiol (2010) 1.02
Use of oral antithrombotic agents among health maintenance organization members with atherosclerotic cardiovascular disease. Arch Intern Med (2002) 1.01
Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb Res (2006) 1.01
Effectiveness of bisphosphonate therapy in a community setting. Bone (2008) 1.01
Mortality risk by functional status and health-related quality of life in patients with rheumatoid arthritis. J Rheumatol (2011) 1.00
Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother (2005) 1.00
Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol (2012) 0.99
Healthcare costs in patients with metastatic lung cancer receiving chemotherapy. BMC Health Serv Res (2011) 0.98
Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. J Am Coll Radiol (2009) 0.96
Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol (2007) 0.96
Adherence with migraine prophylaxis in clinical practice. Pain Pract (2012) 0.95
Cost of illness in patients with metastatic colorectal cancer. J Med Econ (2010) 0.93
Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade? Drug Alcohol Depend (2013) 0.92
Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia. Am J Manag Care (2010) 0.92
Patterns of pharmacotherapy and health care utilization and costs prior to total hip or total knee replacement in patients with osteoarthritis. Arthritis Rheum (2011) 0.91
Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. J Rheumatol (2008) 0.90
Blood pressure control in patients initiating antihypertensive therapy. Ann Pharmacother (2008) 0.89
Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol (2006) 0.88
Adherence to K/DOQI practice guidelines for bone metabolism and disease. Am J Manag Care (2007) 0.88
Characteristics and patterns of healthcare utilization of patients with fibromyalgia in general practitioner settings in Germany. Curr Med Res Opin (2008) 0.88
Risperidone versus Conventional Antipsychotics for Schizophrenia and Schizoaffective Disorder : Symptoms, Quality of Life and Resource Use under Customary Clinical Care. Clin Drug Investig (2004) 0.87
Clinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumonia. J Hosp Med (2010) 0.87
Initial treatment failure in patients with complicated skin and skin structure infections. Surg Infect (Larchmt) (2013) 0.86
Cost-effectiveness of tacrolimus ointment versus pimecrolimus cream in adults with atopic dermatitis. J Drugs Dermatol (2010) 0.86
Discovery and validation of methylation markers for endometrial cancer. Int J Cancer (2014) 0.86
Patterns of initial antibiotic therapy for community-acquired pneumonia in U.S. hospitals, 2000 to 2009. Am J Med Sci (2014) 0.85
Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin (2007) 0.85
Healthcare costs in postmenopausal women with hormone-positive metastatic breast cancer. J Med Econ (2010) 0.84
Economic burden of cardiovascular events and fractures among patients with end-stage renal disease. Curr Med Res Opin (2007) 0.84
Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder. Ann Pharmacother (2012) 0.84
The impact of seizures and adverse effects on global health ratings. Epilepsy Behav (2007) 0.84
Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study. BMC Neurol (2012) 0.84
Magnitude of potentially inappropriate prescribing in Germany among older patients with generalized anxiety disorder. BMC Geriatr (2009) 0.84
Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study. BMC Pulm Med (2012) 0.83
Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies. J Med Econ (2012) 0.83
Self-reported and actual beta-blocker prescribing for heart failure patients: physician predictors. PLoS One (2009) 0.83
Treatment of peripheral neuropathic pain: a simulation model. Eur J Pain (2005) 0.83
Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics (2004) 0.83
Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health Syst Pharm (2002) 0.83
Identification of patients receiving peritoneal dialysis using health insurance claims data. Clin Ther (2009) 0.83
Clinical and economic characteristics of patients with painful neuropathic disorders in Germany. Pain Pract (2008) 0.82
Direct and indirect economic costs among private-sector employees with osteoarthritis. J Occup Environ Med (2011) 0.82
Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study. BMC Psychiatry (2012) 0.82
Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy. Clin J Pain (2007) 0.82
7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series. Vaccine (2009) 0.82
Excess risk of diabetes in persons with hypertension. J Diabetes Complications (2008) 0.82
Immunization predictors in rural adults under 65 years of age. J Health Care Poor Underserved (2003) 0.82
Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis. Clin Ther (2005) 0.81